These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22398051)

  • 21. [Adalimumab therapy in Crohn's disdease].
    Baryshnikov EN; Lazebnik LB; Parfenov AI
    Eksp Klin Gastroenterol; 2009; (5):92-8. PubMed ID: 20205331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
    Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
    Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sjögren's syndrome associated with Crohn's disease successfully treated with adalimumab.
    Tursi A
    J Crohns Colitis; 2012 Mar; 6(2):263. PubMed ID: 22325185
    [No Abstract]   [Full Text] [Related]  

  • 25. Serum adalimumab concentration and clinical remission in patients with Crohn's disease.
    Chiu YL; Rubin DT; Vermeire S; Louis E; Robinson AM; Lomax KG; Pollack PF; Paulson SK
    Inflamm Bowel Dis; 2013 May; 19(6):1112-22. PubMed ID: 23584130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Closure of perianal fistula using adalimumab in a Crohn's disease patient naive to antitumor necrosis factor alpha antibodies.
    Malesci A; Angelucci E; Bonifacio C; Sociale O; Omodei P; Repici A; Balzarini L; Danese S
    Inflamm Bowel Dis; 2009 Jun; 15(6):814-5. PubMed ID: 18831523
    [No Abstract]   [Full Text] [Related]  

  • 27. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
    J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
    Martín-de-Carpi J; Pociello N; Varea V
    J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of opportunistic skin infection with Mycobacterium marinum during adalimumab treatment in a patient with Crohn's disease.
    Kump PK; Högenauer C; Wenzl HH; Petritsch W
    J Crohns Colitis; 2013 Feb; 7(1):e15-8. PubMed ID: 22770648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.
    Emmert MY; Salzberg SP; Emmert LS; Behjati S; Plass A; Felix C; Falk V; Gruenenfelder J
    Eur J Heart Fail; 2009 Nov; 11(11):1106-9. PubMed ID: 19875411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease?
    Tursi A
    Aliment Pharmacol Ther; 2013 Apr; 37(7):752. PubMed ID: 23458532
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
    Tonelli F; Giudici F; Asteria CR
    Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.
    Reenaers C; Louis E; Belaiche J; Seidel L; Keshav S; Travis S
    Aliment Pharmacol Ther; 2013 Apr; 37(7):752-3. PubMed ID: 23458531
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease.
    Casanova MJ; Chaparro M; Valenzuela C; Cisneros C; Gisbert JP
    World J Gastroenterol; 2015 Feb; 21(7):2260-2. PubMed ID: 25717268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment.
    Lie MR; Peppelenbosch MP; West RL; Zelinkova Z; van der Woude CJ
    Aliment Pharmacol Ther; 2014 Nov; 40(10):1202-8. PubMed ID: 25263077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of anti-TNF-α treatment with adalimumab on growth in children with Crohn's disease (CD).
    Malik S; Ahmed SF; Wilson ML; Shah N; Loganathan S; Naik S; Bourke B; Thomas A; Akobeng AK; Fagbemi A; Wilson DC; Russell RK
    J Crohns Colitis; 2012 Apr; 6(3):337-44. PubMed ID: 22405171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.